HK1209674A1 - 用於治療病毒性疾病的雜環基氨甲酰 - Google Patents

用於治療病毒性疾病的雜環基氨甲酰

Info

Publication number
HK1209674A1
HK1209674A1 HK15110554.0A HK15110554A HK1209674A1 HK 1209674 A1 HK1209674 A1 HK 1209674A1 HK 15110554 A HK15110554 A HK 15110554A HK 1209674 A1 HK1209674 A1 HK 1209674A1
Authority
HK
Hong Kong
Prior art keywords
carboxamides
heterocyclyl
viral diseases
treating viral
treating
Prior art date
Application number
HK15110554.0A
Other languages
English (en)
Inventor
胡伯曼
Original Assignee
Novadrug Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novadrug Llc filed Critical Novadrug Llc
Publication of HK1209674A1 publication Critical patent/HK1209674A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK15110554.0A 2012-08-31 2015-10-27 用於治療病毒性疾病的雜環基氨甲酰 HK1209674A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261695869P 2012-08-31 2012-08-31
US201361779595P 2013-03-13 2013-03-13
PCT/US2013/057585 WO2014036443A2 (en) 2012-08-31 2013-08-30 Heterocyclyl carboxamides for treating viral diseases

Publications (1)

Publication Number Publication Date
HK1209674A1 true HK1209674A1 (zh) 2016-04-08

Family

ID=50184664

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15110554.0A HK1209674A1 (zh) 2012-08-31 2015-10-27 用於治療病毒性疾病的雜環基氨甲酰

Country Status (14)

Country Link
US (1) US9511070B2 (zh)
EP (1) EP2922596B1 (zh)
JP (1) JP5976224B2 (zh)
KR (1) KR20150048132A (zh)
CN (1) CN104582794A (zh)
AU (1) AU2013308535B2 (zh)
CA (1) CA2881901C (zh)
EA (1) EA027810B1 (zh)
ES (1) ES2684396T3 (zh)
HK (1) HK1209674A1 (zh)
IL (1) IL237119A (zh)
IN (1) IN2015KN00302A (zh)
WO (1) WO2014036443A2 (zh)
ZA (1) ZA201501430B (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013312477B2 (en) * 2012-09-06 2018-05-31 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US9896450B2 (en) * 2015-05-04 2018-02-20 Ohio State Innovation Foundation Modulators of Clavibacter michiganensis and methods of making and using thereof
US20220363639A1 (en) * 2018-07-31 2022-11-17 The Trustees Of The University Of Pennsylvania Small molecules that sensitize hiv-1 infected cells to antibody dependent cellular cytotoxicity
WO2022053993A2 (en) * 2020-09-12 2022-03-17 Mylan Laboratories Limited Treatments for sars-cov-2 infection (covid-19)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2792399A (en) * 1954-05-29 1957-05-14 Bofors Ab Anilides of heterocyclic compounds
AU3289299A (en) 1998-02-19 1999-09-06 Tularik Inc. Antiviral agents
JP2004519432A (ja) 2000-11-28 2004-07-02 グラクソスミスクライン・ソシエタ・ペル・アチオニ 新規化合物
CN100509797C (zh) 2001-06-11 2009-07-08 病毒化学医药公司 用作黄病毒感染抗病毒剂的噻吩衍生物
WO2003037265A2 (en) * 2001-10-30 2003-05-08 Thomas Jefferson University Method of treating viral infections
AU2003260198A1 (en) * 2002-08-30 2004-03-19 Chiron Corporation Glycopeptide antibiotic and semisynthetic derivatives thereof and their use as antiviral agents
KR100502394B1 (ko) * 2003-06-04 2005-07-19 (주) 비엔씨바이오팜 2-[2-(4-모르포리노)에틸아미노]피리딘 유도체, 그제조방법 및 이를 포함하는 항바이러스용 약학적 조성물
CN1993339B (zh) * 2004-08-06 2013-05-22 大塚制药株式会社 芳香化合物
GB0421908D0 (en) * 2004-10-01 2004-11-03 Angeletti P Ist Richerche Bio New uses
AR055831A1 (es) * 2004-12-30 2007-09-12 Janssen Pharmaceutica Nv Pepirazinilureas y piperidinilureas como moduladores de hidrolasa de amida de acidos grasos
WO2006135993A1 (en) * 2005-06-24 2006-12-28 Gilead Sciences, Inc. Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis c.
WO2009010480A1 (en) * 2007-07-13 2009-01-22 Euroscreen S.A. 1-{2-[(diphenyl)amino]-ethyl}-piperidine-4-carboxylic acid benzylamide derivatives and related compounds as ccr5 agonists for the treatment of immune and inflammatory diseases
JP5642661B2 (ja) * 2009-03-05 2014-12-17 塩野義製薬株式会社 Ｎｐｙｙ５受容体拮抗作用を有するピペリジンおよびピロリジン誘導体
KR101168801B1 (ko) 2009-03-27 2012-07-25 주식회사종근당 신규한 하이드록사메이트 유도체, 이의 제조방법, 및 이를 함유하는 약제학적 조성물
US20120208204A1 (en) * 2009-06-03 2012-08-16 The Brigham And Women's Hospital, Inc. Compositions and Methods for Inhibiting Tumor Growth
WO2011060026A1 (en) 2009-11-12 2011-05-19 Jansen Pharmaceutica Nv Piperazinecarboxamide derivative useful as a modulator of fatty acid amide hydrolase (faah)
WO2011060396A1 (en) * 2009-11-16 2011-05-19 Schering Corporation Aliphatic amines based heterocycles useful as hiv entry blockers
US20130164259A1 (en) * 2009-12-22 2013-06-27 Cliff C. Cheng 1,4-substituted piperazine derivatives and methods of use thereof
WO2011091152A1 (en) 2010-01-22 2011-07-28 Pablo Gastaminza Inhibitors of hepatitis c virus infection
GB201012889D0 (en) * 2010-08-02 2010-09-15 Univ Leuven Kath Antiviral activity of novel bicyclic heterocycles
US9409884B2 (en) 2012-02-01 2016-08-09 Rigel Pharmaceuticals, Inc. 5- or 6-substituted benzofuran-2-carboxamide compounds and methods for using them

Also Published As

Publication number Publication date
IN2015KN00302A (zh) 2015-06-12
EA027810B1 (ru) 2017-09-29
ZA201501430B (en) 2016-01-27
JP2015532652A (ja) 2015-11-12
WO2014036443A2 (en) 2014-03-06
CA2881901C (en) 2017-10-10
IL237119A (en) 2017-08-31
ES2684396T3 (es) 2018-10-02
AU2013308535B2 (en) 2016-10-20
KR20150048132A (ko) 2015-05-06
EA201590297A1 (ru) 2015-08-31
US20150238489A1 (en) 2015-08-27
CA2881901A1 (en) 2014-03-06
CN104582794A (zh) 2015-04-29
JP5976224B2 (ja) 2016-08-23
EP2922596B1 (en) 2018-05-23
WO2014036443A3 (en) 2014-04-24
AU2013308535A1 (en) 2015-02-26
US9511070B2 (en) 2016-12-06
EP2922596A2 (en) 2015-09-30

Similar Documents

Publication Publication Date Title
ZA201500603B (en) Process
EP2890672A4 (en) NEW PROCESS
GB201216921D0 (en) Process
HK1215173A1 (zh) 治療金黃色葡萄球菌相關疾病的方法
GB201207997D0 (en) Process
SG11201500381TA (en) Process
HK1204452A1 (zh) 骨疾病的治療
GB201214326D0 (en) Process
EP2852660A4 (en) PROCESS
HK1209674A1 (zh) 用於治療病毒性疾病的雜環基氨甲酰
HK1199827A1 (zh) 治療婦科疾病的方法
PL2914574T3 (pl) Nowy sposób
SG11201405559TA (en) Component and method for treating viral disease
ZA201502344B (en) Process
GB201219224D0 (en) Process
GB201318062D0 (en) Process
GB201121950D0 (en) Treatment process
GB201215184D0 (en) Therapeutic virus
GB201317561D0 (en) Process
GB201316604D0 (en) Process
HK1206043A1 (zh) 方法
GB201205449D0 (en) Treatment process
GB201212604D0 (en) New treatment
GB201202098D0 (en) New process
GB201105056D0 (en) Treatment process